WELSPUNLIV: Q2 CONS NET PROFIT 1.7B RUPEES VS 130M (YOY)

KIRLFER: Q2 SL NET PROFIT 976M RUPEES VS 885M (YOY)

KIRLFER: Q2 EBITDA 2.23B RUPEES VS 2.14B (YOY); Q2 EBITDA MARGIN 10.9% VS 12.36% (YOY)

KIRLFER: Q2 REVENUE 20.5B RUPEES VS 17.28B (YOY)

SHARDACROP: Q2 CONS NET PROFIT 918M RUPEES VS 743M (YOY)

SHARDACROP: Q2 EBITDA 1.64B RUPEES VS 1.33B (YOY); Q2 EBITDA MARGIN 15.6% VS 14.3% (YOY)


SHARDACROP: Q2 REVENUE 10.5B RUPEES VS 9.3B (YOY)

WELSPUNLIV: Q2 REVENUE 28.4B RUPEES VS 24.4B (YOY)

WELSPUNLIV: Q2 EBITDA 3.38B RUPEES VS 1.53B (YOY); Q2 EBITDA MARGIN 11.9% VS 6.3% (YOY)

SPORTKING: Q2 SL NET PROFIT 964M RUPEES VS 283M (YOY)

SPORTKING: Q2 REVENUE 7.8B RUPEES VS 6.3B (YOY)

SPORTKING: Q2 EBITDA 1.55B RUPEES VS 654M (YOY); Q2 EBITDA MARGIN 19.8% VS 10.4% (YOY)

TATA CHEMICALS, TATA INVESTMENT; Noel Tata Proposes Merging Tata Elec Sys & Tata Consulting Engineers Into Tata Sons - CNBC-TV18 🔴🔴

Noel Tata writes to Tata Sons board

Seeks 2 items on agenda for Nov 26 board meeting

TATA CHEMICALS, TATA INVESTMENT: NOEL Tata Aim Is To Cease Tata Sons Being An NBFC & A Core Investment Company - CNBC-TV18 🔴🔴

DHANUKA AGRITECH Q2 FY27 (STANDALONE) ; NET PROFIT UP 16% AT ₹109 CR (YOY), UP 201% (QOQ)

REVENUE UP 10% AT ₹658 CR (YOY), UP 42% (QOQ)

EBITDA UP 12% AT ₹153 CR (YOY), UP 178% (QOQ)

MARGINS AT 23.3% VS 22.9% (YOY), 11.9% (QOQ)

ABCAPITAL: Q2 CONS NET PROFIT 13B RUPEES VS 8.5B (YOY)

ABCAPITAL: Q2 REVENUE 140B RUPEES VS 106B (YOY)

ABCAPITAL: CO'S CONSOLIDATED REVENUE GREW BY 31% YOY TO ₹ 16,545 CRORE IN Q2 FY27

ADITYA BIRLA CAPITAL Q2 FY27 (CONS.) ; NET PROFIT UP 38% AT ₹1,288 CR (YOY), UP 10% (QOQ)

NII UP 28% AT ₹2,817 CR (YOY), UP 9% (QOQ)

INSURANCE PREMIUM UP 37 % TO 7198 CR YOY, UP 26 % QOQ

EMAMIPAP: Q2 SL NET PROFIT 444M RUPEES VS 66M (YOY)

EMAMIPAP: Q2 EBITDA 929M RUPEES VS 363M (YOY); Q2 EBITDA MARGIN 15.76% VS 8.1% (YOY)

SUNPHARMA: Q2 CONS PBT 44B RUPEES VS 42BB (YOY); CO HAS AN EXCEPTIONAL ITEM OF 12.7B RUPEES

SUNPHARMA: Q2 EBITDA 47.4B RUPEES VS 45.27B (YOY); Q2 EBITDA MARGIN 29.3% VS 31.27% (YOY)

SUNPHARMA: Q2 REVENUE 162B RUPEES VS 144.78B (YOY)

SUN PHARMACEUTICAL INDUSTRIES Q2FY27

REVENUE 16,199.00 CR VS 14,478.00 CR
(+11.89% YOY┃+5.88% QOQ)

EBITDA 4,744.00 CR VS 4,418.00 CR
(+7.38% QOQ)

EBITDA MARGIN 29.30% VS 28.90% QOQ

PAT 1,989.00 CR VS 3,118.00 CR
(-36.21% YOY┃-31.30% QOQ)

EPS 8.30 VS 13.00
(-36.15% YOY┃-31.40% QOQ)

SUN PHARMA Q2 FY27 – RESULTS VS ESTIMATES

• Net Profit: ₹2,501 Cr vs ₹3,085 Cr estimated – Miss by 18.93% 🔻

• Revenue: ₹16,198.7 Cr vs ₹15,766.1 Cr estimated – Beat by 2.74% 🟢

• EBITDA: ₹4,743.5 Cr vs ₹4,403 Cr estimated – Beat by 7.73% 🟢

• EBITDA Margin: 29.3% vs 27.9% estimated – Beat by 140 bps 🟢

SUN PHARMA:

Q2 - US SALES AT $455 M, DOWN 8.2% YOY

GLOBUS SPIRITS Q2 FY27 RESULTS

• Net Profit: ₹14 Cr ↓36% (YoY) | ↓47% (QoQ)

• Revenue: ₹1,099 Cr ↑26% (YoY) | ↓5% (QoQ)

• Operating Profit: ₹60 Cr ↓11% (YoY) | ↓22% (QoQ)

• Operating Margin: 5.5% vs 7.8% (YoY) | 6.7% (QoQ)

• Other Income: ₹3 Cr vs ₹3 Cr (YoY) | ₹2 Cr (QoQ)

• EPS: ₹4.64 ↓39% (YoY) | ↓49% (QoQ)